Nov 2026· Frontiers in Immunology· Vol 17· 0 citations· 45 references
TL;DR
Cervical cancer-specific pathology and mechanistic evidence from other tumor models are synthesized, focusing on myeloid–T-cell crosstalk, T-cell quiescence, ligand-dependent regulation, and endothelial control of immune-cell trafficking.
Abstract
Immune checkpoint blockade has improved the treatment of cervical cancer, yet resistance remains a major clinical challenge. V-domain immunoglobulin suppressor of T-cell activation (VISTA; encoded by VSIR) is an emerging immune checkpoint expressed across myeloid cells, lymphocytes, and vascular endothelium. Its clinical significance appears context-dependent: some studies associate VISTA with unfavorable clinicopathological features, whereas others link abundant intratumoral VISTA-positive immune cells to improved survival. These findings highlight a critical distinction between checkpoint expression and functional immune suppression. This Mini Review synthesizes cervical cancer-specific pathology and mechanistic evidence from other tumor models, focusing on myeloid–T-cell crosstalk, T-cell quiescence, ligand-dependent regulation, and endothelial control of immune-cell trafficking. Interactions involving PSGL-1, VSIG-3, and LRIG1 suggest that VISTA activity varies across cellular and microenvironmental contexts, although their causal roles in cervical cancer remain to be established. Experimental studies support investigating VISTA blockade alongside established checkpoint inhibitors, but available clinical data have not demonstrated efficacy in cervical cancer. Future studies should integrate compartment-specific VISTA assessment, spatial immune profiling, and functional analyses of paired pretreatment and on-treatment specimens to identify VISTA-dependent immune states. Such an approach may provide a basis for biomarker-guided patient selection and rational development of VISTA-targeted immunotherapies.
Work using metastatic mouse models shows that the antitumor response is multifactorial, comprising downregulation of myeloid-mediated CD8+ T-cell suppression along with increased B-cell and plasma cell activation, antibody production, and tertiary lymphoid structure (TLS) maturation.
Y. Senent, R. Manguso· Cancer Research· 0 citations
It is proposed that B cells support anti-tumor immunity when integrated into organized lymphoid niches and engaged in productive T cell-B cell cooperation, whereas they promote immune escape when redirected toward regulatory programs or suppressive myeloid interactions.
Yi-Nuo Wang, Xuan Che, Xiao-Qian Hu et al.· Critical reviews in oncology...· 0 citations
V-domain immunoglobulin suppressor of T-cell activation (VISTA; also termed VSIR, PD-1H or B7-H5) is increasingly recognised as an immune checkpoint whose biological and clinical significance depends less on total expression than on the tumour microenvironment (TME) in which it operates. Rather than acting as a linear...
Ke-Xun Li, Zi-Long Qian, Jian-Zhe Zhang et al.· Frontiers in Immunology· 0 citations
Immunotherapy using immune checkpoint inhibitors has yielded meaningful clinical benefits for patients diagnosed with non-small cell lung cancer (NSCLC). Many patients still develop primary or acquired treatment resistance, a problem strongly tied to immunosuppressive features of the tumour microenvironment (TME). Mult...
Lan-Qing Wang, Si-Si Yan, Fa-Jian He et al.· Cancers· 0 citations
Immune‐cell dynamics within the tumor microenvironment (TME) determine whether immune cells can reach, recognize, and sustain antitumor function against malignant cells under suppressive pressure. These dynamics are shaped by hypoxia, nutrient stress, cytokine and chemokine signaling, stromal architecture, vascular acc...
Pin Guo, Yi-Zhao Xie, R. Song et al.· MedComm· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.